Entering text into the input field will update the search result below

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2022 Update

John Vincent profile picture
John Vincent


  • Glenview Capital Management’s 13F portfolio value increased from $4B to $4.51B this quarter. The number of positions decreased from 54 to 53.
  • They added Universal Health Services, Meta Platforms, and Alphabet while reducing Aptiv and dropping Amazon. They also added a large short position through Puts on the SPDR S&P 500.
  • The top three stakes are Cigna, Tenet Healthcare, and SPDR S&P 500 Index ETF Puts. They add up to ~31% of the portfolio.

Red Stethoscope Forming An American Dollar Sign On White Background


This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 2/14/2023. Please visit our

Larry Robbins - Glenview Capital's Q4 2022 13F Report Q/Q Comparison

Larry Robbins - Glenview Capital's Q4 2022 13F Report Q/Q Comparison (John Vincent (author))

This article was written by

John Vincent profile picture
Focused on analyzing 13F reports & building tools to help DIY investors generate absolute returns through exploiting inefficiency, volatility, and momentum.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMZN, GOOGL, META either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.